​

Haemonetics (HAE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HAE Stock Forecast

Haemonetics (HAE) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $86.60, with a high of $94.00 and a low of $80.00. This represents a 45.57% increase from the last price of $59.49.

$55 $63 $71 $79 $87 $95 High: $94 Avg: $86.6 Low: $80 Last Closed Price: $59.49

HAE Stock Rating

Haemonetics stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (50.00%), 10 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 10 10 Strong Sell Sell Hold Buy Strong Buy

HAE Price Target Upside V Benchmarks

TypeNameUpside
StockHaemonetics45.57%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks25.69%

Price Target Trends

1M3M12M
# Anlaysts-69
Avg Price Target-$89.50$87.00
Last Closing Price$59.49$59.49$59.49
Upside/Downside-50.45%46.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26434--11
Feb, 26434--11
Jan, 26434--11
Dec, 25542--11
Nov, 25541-111
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 06, 2026Robert W. Baird$81.00$61.4031.92%36.16%
Feb 06, 2026Barrington$94.00$65.0244.57%58.01%
Feb 06, 2026Mizuho Securities$80.00$65.0223.04%34.48%
Jan 12, 2026Barrington$93.00$82.0313.37%56.33%
Dec 17, 2025Mizuho Securities$90.00$81.1110.96%51.29%
Dec 15, 2025Robert W. Baird$99.00$80.3323.24%66.41%
Nov 14, 2025Andrew CooperRaymond James$90.00$73.9121.77%51.29%
Nov 06, 2025BTIG$88.00$66.2032.93%47.92%
Aug 07, 2025Mike MatsonNeedham$68.00$55.6422.21%14.30%
Nov 08, 2024Andrew CooperRaymond James$120.00$74.8360.36%101.71%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 06, 2026CitigroupNeutralNeutralhold
Dec 15, 2025NeedhamBuyHolddowngrade
Dec 11, 2025CitigroupUnderperformNeutraldowngrade
Nov 14, 2025Raymond JamesOutperformOutperformhold
Nov 06, 2025BTIGBuyBuyhold
Aug 11, 2025Raymond JamesStrong BuyOutperformdowngrade
Aug 07, 2025NeedhamBuyBuyhold
Mar 18, 2025NeedhamBuyBuyhold
Nov 08, 2024Raymond JamesStrong Buyupgrade
Sep 11, 2024Bank of America SecuritiesNeutralinitialise

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$1.57$0.85$2.27$2.32$3.31---
Avg Forecast$2.56$2.53$2.97$3.96$4.59$5.28$6.07$7.55
High Forecast$2.62$2.59$3.02$4.03$4.60$5.36$6.66$7.68
Low Forecast$2.53$2.50$2.92$3.95$4.57$5.20$5.34$7.42
Surprise %-38.67%-66.40%-23.57%-41.41%-27.89%---

Revenue Forecast

$850M $1B $1B $1B $2B $2B Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$870.46M$993.20M$1.17B$1.31B$1.36B---
Avg Forecast$868.82M$986.15M$1.15B$1.30B$1.39B$1.44B$1.57B$1.81B
High Forecast$883.98M$1.00B$1.17B$1.31B$1.40B$1.46B$1.57B$1.84B
Low Forecast$859.55M$975.63M$1.14B$1.28B$1.38B$1.41B$1.57B$1.79B
Surprise %0.19%0.71%1.19%1.08%-2.36%---

Net Income Forecast

$-50M $40M $130M $220M $310M $400M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$79.47M$43.38M$115.40M$117.56M$167.68M---
Avg Forecast$89.59M$-3.10M$152.47M$123.81M$235.67M$271.40M$308.39M$388.05M
High Forecast$107.51M$3.75M$155.16M$148.57M$236.44M$275.29M$342.43M$394.89M
Low Forecast$71.67M$-9.95M$149.83M$99.05M$234.90M$267.50M$274.35M$381.33M
Surprise %-11.30%-1498.81%-24.31%-5.05%-28.85%---

HAE Forecast FAQ

Is Haemonetics stock a buy?

Haemonetics stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 10 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Haemonetics is a favorable investment for most analysts.

What is Haemonetics's price target?

Haemonetics's price target, set by 20 Wall Street analysts, averages $86.6 over the next 12 months. The price target range spans from $80 at the low end to $94 at the high end, suggesting a potential 45.57% change from the previous closing price of $59.49.

How does Haemonetics stock forecast compare to its benchmarks?

Haemonetics's stock forecast shows a 45.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical instruments & supplies stocks industry (25.69%).

What is the breakdown of analyst ratings for Haemonetics over the past three months?

  • March 2026: 36.36% Strong Buy, 27.27% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 36.36% Strong Buy, 27.27% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 36.36% Strong Buy, 27.27% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.

What is Haemonetics’s EPS forecast?

Haemonetics's average annual EPS forecast for its fiscal year ending in March 2026 is $5.28, marking a 59.52% increase from the reported $3.31 in 2025. Estimates for the following years are $6.07 in 2027, and $7.55 in 2028.

What is Haemonetics’s revenue forecast?

Haemonetics's average annual revenue forecast for its fiscal year ending in March 2026 is $1.44B, reflecting a 5.67% increase from the reported $1.36B in 2025. The forecast for 2027 is $1.57B, and $1.81B for 2028.

What is Haemonetics’s net income forecast?

Haemonetics's net income forecast for the fiscal year ending in March 2026 stands at $271.4M, representing an 61.86% increase from the reported $167.68M in 2025. Projections indicate $308.39M in 2027, and $388.05M in 2028.